Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of growth factors during hepatitis C anti-viral therapy.

Alimentary pharmacology & therapeutics - 1 Oct 2006

Chapko M K, Dominitz J A

Abstract excerpt

BACKGROUND: Although the current standard of care for controlling anaemia and neutropenia during anti-viral therapy for hepatitis C is to use dose reduction of ribavirin and pegylated interferon, respectively, erythropoietin and granulocyte colony-stimulating factor are now being advocated as alt...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cost-Benefit Analysis
Share to Decision Support Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erythropoietin

Share to Genotype

Share to Granulocyte Colony-Stimulating Factor

Share to Hepatitis C

Share to Treatment Outcome

Source

Identifiers

PMID: 16984501
DOI: 10.1111/j.1365-2036.2006.03089.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16984501-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Cost-effectiveness of growth factors during hepatitis C anti-viral therapy.PMID 16984501Read ↗

Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.Semantic proximity Read ↗

The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.Semantic proximity Read ↗

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.Semantic proximity Read ↗

Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.Semantic proximity Read ↗

Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.Semantic proximity Read ↗

Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.Semantic proximity Read ↗

The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.